{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28anti-CTLA4%29+monoclonal+antibody", "query": { "intervention": "MDX-010 (anti-CTLA4) monoclonal antibody" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 190, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28anti-CTLA4%29+monoclonal+antibody&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-11T12:59:01.069Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02496208", "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Bladder Urothelial Carcinoma", "Clear Cell Renal Cell Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Sarcomatoid Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Malignant Genitourinary System Neoplasm", "Malignant Solid Neoplasm", "Penile Carcinoma", "Penile Squamous Cell Carcinoma", "Renal Cell Carcinoma", "Renal Pelvis Urothelial Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Penile Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Renal Pelvis and Ureter Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Ureter Urothelial Carcinoma", "Urethral Urothelial Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2015-07-22", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 8, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02496208" }, { "nct_id": "NCT03468985", "title": "Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-05-07", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 468, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Jonesboro, Arkansas + 301 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03468985" }, { "nct_id": "NCT03146650", "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Salivary Gland Carcinoma", "Minor Salivary Gland Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage IV Major Salivary Gland Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVC Major Salivary Gland Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2017-05-19", "completion_date": "2025-08-11", "has_results": true, "last_update_posted_date": "2024-01-18", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03146650" }, { "nct_id": "NCT07128680", "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Advanced Sarcomatoid Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DIETARY_SUPPLEMENT", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-03-23", "completion_date": "2028-08-25", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128680" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT00871481", "title": "Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "therapeutic cytotoxic T lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-02", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00871481" }, { "nct_id": "NCT03958383", "title": "IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "hu14.18-IL2", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-01-30", "completion_date": "2025-12-09", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958383" }, { "nct_id": "NCT01750580", "title": "Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CANCER, NOS" ], "interventions": [ { "name": "Lirilumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-12", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-07-22", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 6, "location_summary": "Tampa, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750580" }, { "nct_id": "NCT00094653", "title": "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Metastases" ], "interventions": [ { "name": "MDX-010 (anti-CTLA4) monoclonal antibody", "type": "DRUG" }, { "name": "MDX-1379 (gp100) Melanoma Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1783, "start_date": "2004-09", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-07-11", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 110, "location_summary": "Tucson, Arizona • Duarte, California • Encinitas, California + 78 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094653" }, { "nct_id": "NCT01693783", "title": "Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Squamous Cell Carcinoma", "Human Papillomavirus Infection", "Recurrent Cervical Carcinoma", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVB Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2012-12-03", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-11T12:59:01.069Z", "location_count": 5, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01693783" } ] }